Claudia Stege

MSC.

20172018
If you made any changes in Pure these will be visible here soon.

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2017 2018

CD38-targeting antibodies in multiple myeloma: mechanisms of action and clinical experience

Frerichs, K. A., Nagy, N. A., Lindenbergh, P. L., Bosman, P., Marin Soto, J., Broekmans, M., Groen, R. W. J., Themeli, M., Nieuwenhuis, L., Stege, C., Nijhof, I. S., Mutis, T., Zweegman, S., Lokhorst, H. M. & van de Donk, N. W. C. J., Mar 2018, In : Expert Review of Clinical Immunology. 14, 3, p. 197-206 10 p.

Research output: Contribution to journalArticleAcademicpeer-review

FEASIBILITY AND EFFICACY OF DOSE ADJUSTED MELPHALAN - PREDNISONE - BORTEZOMIB IN PATIENTS >= 75 YEARS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA; PRELIMINARY RESULTS OF THE PHASE II HOVON 123 STUDY

Zweegman, S., Levin, M. -D., Klein, S. K., de Waal, E. G., Eeltink, C. M., Ypma, P. F., Dijk, A. C., Westerman, M., Deenik, W., Tanis, B., Slee-Valentijn, M. S., Minnema, M. C., Visser-Wisselaar, H., Stege, C., van de Donk, N. W., Nasserinejad, K. & Sonneveld, P., 26 Jun 2017, In : Haematologica. 102, p. 112-113

Research output: Contribution to journalMeeting AbstractAcademic

Frailty predicts survival and toxicity in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation; report of the HOVON-87/NMSG-18 study group

Stege, C. A. M., Van Der Holt, B., Mellqvist, U. H., Levin, M. D., Salomo, M., Abildgaard, N., Bos, G., Visser-Wisselaar, H., Hansson, M., Van Der Velden, A., Deenik, W., Gruber, A., Coenen, J. L. L. M., Plesner, T., Klein, S., Tanis, B., Szatkowski, D. L., Brouwer, R., Westerman, M., Leijs, M. B. & 11 othersSinnige, H., Haukaas, E., Van Der Hem, K., Durian, M., Mattijssen, V., Gimsing, P., Van De Donk, N. W. C. J., Stevens-Kroef, M., Sonneveld, P., Waage, A. & Zweegman, S., 2017, Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH. (Blood. Conference: 59th Annual Meeting of the American Society of Hematology, ASH; vol. 130).

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Health-related quality of life in non-transplant eligible newly diagnosed multiple myeloma patients treated with melphalan/prednisolone plus either thalidomide or lenalidomide; results of the HOVON87/NMSG18 study

Nielsen, L., Stege, C., Witte, B., Holt, B., Mellqvist, U-H., Salomo, M., Levin, M-D., Hansson, M., Plesner, T., Szatkowski, D., Haukas, E., Gimsing, P., Sonneveld, P., Abildgaard, N., Waage, A. & Zweegman, S., 2017, 2 p. (Quality of life research. Conference: 24th annual conference of the international society for quality of life research, ISOQOL 2017. United states; vol. 26)

Research output: Book/ReportBookAcademicpeer-review